Baseline characteristics
| Advanced CSCC (N=193) | |
| Median age, years (range) | 72.0 (38–96) |
| Male, n (%) | 161 (83.4) |
| Eastern Cooperative Oncology Group performance status score, n (%) | |
| 0 | 86 (44.6) |
| 1 | 107 (55.4) |
| Primary CSCC site: head and neck, n (%) | 131 (67.9) |
| Metastatic CSCC, n (%) | 115 (59.6) |
| Locally advanced CSCC, n (%) | 78 (40.4) |
| Patients with cemiplimab as first-line therapy, n (%) | 128 (66.3) |
| Patients with prior systemic therapy, n (%)* | 65 (33.7) |
| Median duration of exposure to cemiplimab, weeks (range) | 51.1 (2.0–109.3) |
| Median number of doses of cemiplimab administered (range) | 18.0 (1–48) |
*Settings for prior lines of therapy included metastatic disease, adjuvant, chemotherapy with concurrent radiation, or other, and the most common types of prior systemic therapy were platinum compounds (n=46/65 [70.8%]) and monoclonal antibodies (n=18/65 [27.7%]).
CSCC, cutaneous squamous cell carcinoma.